APLS vs. ITCI, VTRS, GMAB, MRNA, RDY, SRPT, PCVX, QGEN, ROIV, and ASND
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Intra-Cellular Therapies (ITCI), Viatris (VTRS), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Apellis Pharmaceuticals vs.
Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.
Intra-Cellular Therapies received 177 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. However, 67.25% of users gave Apellis Pharmaceuticals an outperform vote while only 67.01% of users gave Intra-Cellular Therapies an outperform vote.
In the previous week, Apellis Pharmaceuticals had 9 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 18 mentions for Apellis Pharmaceuticals and 9 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.66 beat Apellis Pharmaceuticals' score of 0.36 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media.
Intra-Cellular Therapies has higher revenue and earnings than Apellis Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Apellis Pharmaceuticals currently has a consensus target price of $46.71, indicating a potential upside of 70.46%. Intra-Cellular Therapies has a consensus target price of $103.62, indicating a potential downside of 18.94%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Apellis Pharmaceuticals is more favorable than Intra-Cellular Therapies.
96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Intra-Cellular Therapies has a net margin of -14.07% compared to Apellis Pharmaceuticals' net margin of -34.97%. Intra-Cellular Therapies' return on equity of -9.93% beat Apellis Pharmaceuticals' return on equity.
Apellis Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
Summary
Apellis Pharmaceuticals and Intra-Cellular Therapies tied by winning 9 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:APLS) was last updated on 2/18/2025 by MarketBeat.com Staff